Could an allergy pill and diabetes drug fix MS nerve damage?

NCT ID NCT05131828

Completed Disease control Sponsor: Cambridge University Hospitals NHS Foundation Trust Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This completed Phase 2 trial tested whether combining two common drugs—metformin (for diabetes) and clemastine (an antihistamine)—can help repair the protective lining of nerve cells in people with relapsing-remitting multiple sclerosis. The 70 participants continued their usual MS treatments while taking the combo or a placebo for 24 weeks. Researchers measured changes in nerve signals to see if the drugs promote repair.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: metformin and clemastine combination
What this could lead to: If it works, this could point toward a treatment that repairs nerve damage in multiple sclerosis, potentially slowing or reversing disability progression.
What could go wrong: This is a small, early-phase trial (70 people) focused on measuring nerve signals, not clinical improvement. The drugs may not show a clear benefit, and results may not apply to all MS patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

multiple sclerosis relapsing-remitting multiple sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE SCLEROSIS

Contacts and locations

Locations

Addenbrooke's Hospital

Cambridge, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.